01:40 AM EST, 11/11/2026 (MT Newswires) -- Norway-listed biotechnology company Circio Holding (CRNA.OL) partnered with US-based Solid Biosciences to combine their respective platforms to develop systemic gene therapy for genetic heart disease. Under the research collaboration, Circio's circular RNA gene expression platform, circVec, will integrate with Solid's adeno-associated virus capsid, Polaris-101TM, according to a Wednesday release. The technologies will be combined to evaluate potential synergies in vitro and in vivo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.